Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

LILIAM HERNANDEZ

Allopathic & Osteopathic Physicians Family Medicine

NPI
1194913806
CMS profile
99162
Location
PINECREST, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$52.48

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $52.48 1

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
Novo Nordisk Inc $52.48 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

LILIAM HERNANDEZ

NPI 1194913806 · CMS profile ID 99162

Allopathic & Osteopathic Physicians / Family Medicine

PINECREST, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1194913806?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
LILIAM HERNANDEZ, NPI 1194913806, CMS profile ID 99162. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1194913806?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). LILIAM HERNANDEZ, NPI 1194913806, CMS profile ID 99162. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1194913806?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
LILIAM HERNANDEZ, NPI 1194913806, CMS profile ID 99162, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1194913806?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $52.48 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novo Nordisk Inc $52.4807/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1003073063 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2021 $20.38 1
PY2022 $11.77 1
PY2023 $52.48 1
PY2025 $108.51 2

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2021, 2022, 2023, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2021 , PY2022 , PY2023 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $58.13 1
PY2025 Principal investigator $357,395.05 105
PY2024 Principal investigator $31,577.28 11
PY2023 Principal investigator $56,157.55 11
PY2022 Principal investigator $228,144.44 112
PY2021 Principal investigator $243,220.87 43
PY2020 Principal investigator $212,607.75 52
PY2019 Principal investigator $155,246.27 19

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

112 records in PY2022

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 GlaxoSmithKline, LLC. $27,015.30 12/12/2022 Non-covered Recipient Entity
BCSD RESEARCH INC
A MULTI-CENTRE LONG-TERM EXTENSION STUDY TO ASSESS THE SAFETY AND EFFI No dispute reported 06/30/2026 965505001
Principal investigator 1 PFIZER INC. $5,364.00 11/24/2022 Non-covered Recipient Entity
BCSD RESEARCH INC
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 949731739
Principal investigator 1 GlaxoSmithKline, LLC. $1,493.10 11/21/2022 Non-covered Recipient Entity
BCSD RESEARCH INC
A MULTI-CENTRE LONG-TERM EXTENSION STUDY TO ASSESS THE SAFETY AND EFFI No dispute reported 06/30/2026 943959459
Principal investigator 1 PFIZER INC. $13,079.34 11/05/2022 Non-covered Recipient Entity
BCSD RESEARCH INC
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 949735498
Principal investigator 1 PFIZER INC. $5,364.00 09/23/2022 Non-covered Recipient Entity
BCSD RESEARCH INC
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 949742347
Principal investigator 1 GlaxoSmithKline, LLC. $10,780.20 09/22/2022 Non-covered Recipient Entity
BCSD RESEARCH INC
A MULTI-CENTRE LONG-TERM EXTENSION STUDY TO ASSESS THE SAFETY AND EFFI No dispute reported 06/30/2026 943959501
Principal investigator 1 GlaxoSmithKline, LLC. $4,217.40 09/02/2022 Non-covered Recipient Entity
BCSD RESEARCH INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943959535
Principal investigator 1 GlaxoSmithKline, LLC. $2,309.40 08/19/2022 Non-covered Recipient Entity
BCSD RESEARCH INC
A MULTI-CENTRE LONG-TERM EXTENSION STUDY TO ASSESS THE SAFETY AND EFFI No dispute reported 06/30/2026 943959401
Principal investigator 1 PFIZER INC. $4,000.00 08/10/2022 Non-covered Recipient Entity
BCSD RESEARCH INC
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 949737517
Principal investigator 1 GlaxoSmithKline, LLC. $3,501.00 08/01/2022 Non-covered Recipient Entity
BCSD RESEARCH INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943959473
Principal investigator 1 GlaxoSmithKline, LLC. $1,096.20 07/20/2022 Non-covered Recipient Entity
BCSD RESEARCH INC
A MULTI-CENTRE LONG-TERM EXTENSION STUDY TO ASSESS THE SAFETY AND EFFI No dispute reported 06/30/2026 943959439
Principal investigator 1 GlaxoSmithKline, LLC. $24,380.10 07/05/2022 Non-covered Recipient Entity
BCSD RESEARCH INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943959443
Principal investigator 1 GlaxoSmithKline, LLC. $1,105.10 06/24/2022 Non-covered Recipient Entity
BCSD RESEARCH INC
A 24-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE-BLIND, EFFICACY AN No dispute reported 06/30/2026 943959503
Principal investigator 1 GlaxoSmithKline, LLC. $42.70 06/17/2022 Non-covered Recipient Entity
BCSD RESEARCH INC
A MULTI-CENTRE LONG-TERM EXTENSION STUDY TO ASSESS THE SAFETY AND EFFI No dispute reported 06/30/2026 943959349
Principal investigator 1 GlaxoSmithKline, LLC. $1,659.00 06/17/2022 Non-covered Recipient Entity
BCSD RESEARCH INC
A MULTI-CENTRE LONG-TERM EXTENSION STUDY TO ASSESS THE SAFETY AND EFFI No dispute reported 06/30/2026 943959365
Principal investigator 1 GlaxoSmithKline, LLC. $1,659.00 06/17/2022 Non-covered Recipient Entity
BCSD RESEARCH INC
A MULTI-CENTRE LONG-TERM EXTENSION STUDY TO ASSESS THE SAFETY AND EFFI No dispute reported 06/30/2026 943959391
Principal investigator 1 GlaxoSmithKline, LLC. $430.00 06/17/2022 Non-covered Recipient Entity
BCSD RESEARCH INC
A MULTI-CENTRE LONG-TERM EXTENSION STUDY TO ASSESS THE SAFETY AND EFFI No dispute reported 06/30/2026 943959397
Principal investigator 1 GlaxoSmithKline, LLC. $430.00 06/17/2022 Non-covered Recipient Entity
BCSD RESEARCH INC
A MULTI-CENTRE LONG-TERM EXTENSION STUDY TO ASSESS THE SAFETY AND EFFI No dispute reported 06/30/2026 943959403
Principal investigator 1 GlaxoSmithKline, LLC. $430.00 06/17/2022 Non-covered Recipient Entity
BCSD RESEARCH INC
A MULTI-CENTRE LONG-TERM EXTENSION STUDY TO ASSESS THE SAFETY AND EFFI No dispute reported 06/30/2026 943959417
Principal investigator 1 GlaxoSmithKline, LLC. $430.00 06/17/2022 Non-covered Recipient Entity
BCSD RESEARCH INC
A MULTI-CENTRE LONG-TERM EXTENSION STUDY TO ASSESS THE SAFETY AND EFFI No dispute reported 06/30/2026 943959433
Principal investigator 1 GlaxoSmithKline, LLC. $1,218.00 06/17/2022 Non-covered Recipient Entity
BCSD RESEARCH INC
A MULTI-CENTRE LONG-TERM EXTENSION STUDY TO ASSESS THE SAFETY AND EFFI No dispute reported 06/30/2026 943959469
Principal investigator 1 GlaxoSmithKline, LLC. $430.00 06/17/2022 Non-covered Recipient Entity
BCSD RESEARCH INC
A MULTI-CENTRE LONG-TERM EXTENSION STUDY TO ASSESS THE SAFETY AND EFFI No dispute reported 06/30/2026 943959471
Principal investigator 1 GlaxoSmithKline, LLC. $1,283.00 06/17/2022 Non-covered Recipient Entity
BCSD RESEARCH INC
A MULTI-CENTRE LONG-TERM EXTENSION STUDY TO ASSESS THE SAFETY AND EFFI No dispute reported 06/30/2026 943959493
Principal investigator 1 GlaxoSmithKline, LLC. $1,283.00 06/17/2022 Non-covered Recipient Entity
BCSD RESEARCH INC
A MULTI-CENTRE LONG-TERM EXTENSION STUDY TO ASSESS THE SAFETY AND EFFI No dispute reported 06/30/2026 943959527
Principal investigator 1 GlaxoSmithKline, LLC. $1,283.00 06/17/2022 Non-covered Recipient Entity
BCSD RESEARCH INC
A MULTI-CENTRE LONG-TERM EXTENSION STUDY TO ASSESS THE SAFETY AND EFFI No dispute reported 06/30/2026 943959537
Principal investigator 1 GlaxoSmithKline, LLC. $3,092.40 06/01/2022 Non-covered Recipient Entity
BCSD RESEARCH INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943959381
Principal investigator 1 GlaxoSmithKline, LLC. $2,475.90 05/02/2022 Non-covered Recipient Entity
BCSD RESEARCH INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943959441
Principal investigator 1 GlaxoSmithKline, LLC. $20,495.04 04/07/2022 Non-covered Recipient Entity
LA SALUD RESEARCH CLINIC INC
A PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P No dispute reported 06/30/2026 943959335
Principal investigator 1 GlaxoSmithKline, LLC. $10,477.20 04/07/2022 Non-covered Recipient Entity
LA SALUD RESEARCH CLINIC INC
A PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P No dispute reported 06/30/2026 943959341
Principal investigator 1 GlaxoSmithKline, LLC. $2,000.00 04/07/2022 Non-covered Recipient Entity
LA SALUD RESEARCH CLINIC INC
A PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P No dispute reported 06/30/2026 943959343
Principal investigator 1 GlaxoSmithKline, LLC. $1,167.72 03/24/2022 Non-covered Recipient Entity
LA SALUD RESEARCH CLINIC INC
A PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P No dispute reported 06/30/2026 943959339
Principal investigator 1 PFIZER INC. $6,264.00 03/24/2022 Non-covered Recipient Entity
BCSD RESEARCH INC
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 949738005
Principal investigator 1 GlaxoSmithKline, LLC. $1,461.12 03/17/2022 Non-covered Recipient Entity
LA SALUD RESEARCH CLINIC INC
A PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P No dispute reported 06/30/2026 943959331
Principal investigator 1 GlaxoSmithKline, LLC. $4,491.96 03/17/2022 Non-covered Recipient Entity
LA SALUD RESEARCH CLINIC INC
A PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P No dispute reported 06/30/2026 943959337
Principal investigator 1 GlaxoSmithKline, LLC. $13,150.08 03/17/2022 Non-covered Recipient Entity
LA SALUD RESEARCH CLINIC INC
A PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P No dispute reported 06/30/2026 943959345
Principal investigator 1 GlaxoSmithKline, LLC. $11,954.40 03/03/2022 Non-covered Recipient Entity
LA SALUD RESEARCH CLINIC INC
A PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P No dispute reported 06/30/2026 943959347
Principal investigator 1 GlaxoSmithKline, LLC. $259.00 03/01/2022 Non-covered Recipient Entity
BCSD RESEARCH INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943959351
Principal investigator 1 GlaxoSmithKline, LLC. $259.00 03/01/2022 Non-covered Recipient Entity
BCSD RESEARCH INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943959355
Principal investigator 1 GlaxoSmithKline, LLC. $259.00 03/01/2022 Non-covered Recipient Entity
BCSD RESEARCH INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943959357
Principal investigator 1 GlaxoSmithKline, LLC. $464.00 03/01/2022 Non-covered Recipient Entity
BCSD RESEARCH INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943959359
Principal investigator 1 GlaxoSmithKline, LLC. $259.00 03/01/2022 Non-covered Recipient Entity
BCSD RESEARCH INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943959361
Principal investigator 1 GlaxoSmithKline, LLC. $519.00 03/01/2022 Non-covered Recipient Entity
BCSD RESEARCH INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943959363
Principal investigator 1 GlaxoSmithKline, LLC. $259.00 03/01/2022 Non-covered Recipient Entity
BCSD RESEARCH INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943959367
Principal investigator 1 GlaxoSmithKline, LLC. $360.00 03/01/2022 Non-covered Recipient Entity
BCSD RESEARCH INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943959369
Principal investigator 1 GlaxoSmithKline, LLC. $259.00 03/01/2022 Non-covered Recipient Entity
BCSD RESEARCH INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943959371
Principal investigator 1 GlaxoSmithKline, LLC. $259.00 03/01/2022 Non-covered Recipient Entity
BCSD RESEARCH INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943959373
Principal investigator 1 GlaxoSmithKline, LLC. $259.00 03/01/2022 Non-covered Recipient Entity
BCSD RESEARCH INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943959375
Principal investigator 1 GlaxoSmithKline, LLC. $519.00 03/01/2022 Non-covered Recipient Entity
BCSD RESEARCH INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943959377
Principal investigator 1 GlaxoSmithKline, LLC. $519.00 03/01/2022 Non-covered Recipient Entity
BCSD RESEARCH INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943959379
Principal investigator 1 GlaxoSmithKline, LLC. $704.00 03/01/2022 Non-covered Recipient Entity
BCSD RESEARCH INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943959383
Principal investigator 1 GlaxoSmithKline, LLC. $259.00 03/01/2022 Non-covered Recipient Entity
BCSD RESEARCH INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943959385
Principal investigator 1 GlaxoSmithKline, LLC. $464.00 03/01/2022 Non-covered Recipient Entity
BCSD RESEARCH INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943959387
Principal investigator 1 GlaxoSmithKline, LLC. $464.00 03/01/2022 Non-covered Recipient Entity
BCSD RESEARCH INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943959389
Principal investigator 1 GlaxoSmithKline, LLC. $259.00 03/01/2022 Non-covered Recipient Entity
BCSD RESEARCH INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943959393
Principal investigator 1 GlaxoSmithKline, LLC. $464.00 03/01/2022 Non-covered Recipient Entity
BCSD RESEARCH INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943959395
Principal investigator 1 GlaxoSmithKline, LLC. $259.00 03/01/2022 Non-covered Recipient Entity
BCSD RESEARCH INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943959399
Principal investigator 1 GlaxoSmithKline, LLC. $519.00 03/01/2022 Non-covered Recipient Entity
BCSD RESEARCH INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943959405
Principal investigator 1 GlaxoSmithKline, LLC. $259.00 03/01/2022 Non-covered Recipient Entity
BCSD RESEARCH INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943959407
Principal investigator 1 GlaxoSmithKline, LLC. $259.00 03/01/2022 Non-covered Recipient Entity
BCSD RESEARCH INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943959409
Principal investigator 1 GlaxoSmithKline, LLC. $464.00 03/01/2022 Non-covered Recipient Entity
BCSD RESEARCH INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943959411
Principal investigator 1 GlaxoSmithKline, LLC. $519.00 03/01/2022 Non-covered Recipient Entity
BCSD RESEARCH INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943959415
Principal investigator 1 GlaxoSmithKline, LLC. $259.00 03/01/2022 Non-covered Recipient Entity
BCSD RESEARCH INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943959419
Principal investigator 1 GlaxoSmithKline, LLC. $464.00 03/01/2022 Non-covered Recipient Entity
BCSD RESEARCH INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943959421
Principal investigator 1 GlaxoSmithKline, LLC. $259.00 03/01/2022 Non-covered Recipient Entity
BCSD RESEARCH INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943959423
Principal investigator 1 GlaxoSmithKline, LLC. $704.00 03/01/2022 Non-covered Recipient Entity
BCSD RESEARCH INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943959425
Principal investigator 1 GlaxoSmithKline, LLC. $259.00 03/01/2022 Non-covered Recipient Entity
BCSD RESEARCH INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943959427
Principal investigator 1 GlaxoSmithKline, LLC. $519.00 03/01/2022 Non-covered Recipient Entity
BCSD RESEARCH INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943959429
Principal investigator 1 GlaxoSmithKline, LLC. $259.00 03/01/2022 Non-covered Recipient Entity
BCSD RESEARCH INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943959431
Principal investigator 1 GlaxoSmithKline, LLC. $464.00 03/01/2022 Non-covered Recipient Entity
BCSD RESEARCH INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943959435
Principal investigator 1 GlaxoSmithKline, LLC. $259.00 03/01/2022 Non-covered Recipient Entity
BCSD RESEARCH INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943959437
Principal investigator 1 GlaxoSmithKline, LLC. $519.00 03/01/2022 Non-covered Recipient Entity
BCSD RESEARCH INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943959445
Principal investigator 1 GlaxoSmithKline, LLC. $259.00 03/01/2022 Non-covered Recipient Entity
BCSD RESEARCH INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943959447
Principal investigator 1 GlaxoSmithKline, LLC. $464.00 03/01/2022 Non-covered Recipient Entity
BCSD RESEARCH INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943959449
Principal investigator 1 GlaxoSmithKline, LLC. $464.00 03/01/2022 Non-covered Recipient Entity
BCSD RESEARCH INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943959451
Principal investigator 1 GlaxoSmithKline, LLC. $464.00 03/01/2022 Non-covered Recipient Entity
BCSD RESEARCH INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943959455
Principal investigator 1 GlaxoSmithKline, LLC. $259.00 03/01/2022 Non-covered Recipient Entity
BCSD RESEARCH INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943959457
Principal investigator 1 GlaxoSmithKline, LLC. $704.00 03/01/2022 Non-covered Recipient Entity
BCSD RESEARCH INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943959461
Principal investigator 1 GlaxoSmithKline, LLC. $519.00 03/01/2022 Non-covered Recipient Entity
BCSD RESEARCH INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943959463
Principal investigator 1 GlaxoSmithKline, LLC. $259.00 03/01/2022 Non-covered Recipient Entity
BCSD RESEARCH INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943959465
Principal investigator 1 GlaxoSmithKline, LLC. $464.00 03/01/2022 Non-covered Recipient Entity
BCSD RESEARCH INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943959467
Principal investigator 1 GlaxoSmithKline, LLC. $259.00 03/01/2022 Non-covered Recipient Entity
BCSD RESEARCH INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943959475
Principal investigator 1 GlaxoSmithKline, LLC. $259.00 03/01/2022 Non-covered Recipient Entity
BCSD RESEARCH INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943959477
Principal investigator 1 GlaxoSmithKline, LLC. $519.00 03/01/2022 Non-covered Recipient Entity
BCSD RESEARCH INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943959479
Principal investigator 1 GlaxoSmithKline, LLC. $519.00 03/01/2022 Non-covered Recipient Entity
BCSD RESEARCH INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943959481
Principal investigator 1 GlaxoSmithKline, LLC. $519.00 03/01/2022 Non-covered Recipient Entity
BCSD RESEARCH INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943959483
Principal investigator 1 GlaxoSmithKline, LLC. $464.00 03/01/2022 Non-covered Recipient Entity
BCSD RESEARCH INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943959485
Principal investigator 1 GlaxoSmithKline, LLC. $259.00 03/01/2022 Non-covered Recipient Entity
BCSD RESEARCH INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943959487
Principal investigator 1 GlaxoSmithKline, LLC. $259.00 03/01/2022 Non-covered Recipient Entity
BCSD RESEARCH INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943959489
Principal investigator 1 GlaxoSmithKline, LLC. $259.00 03/01/2022 Non-covered Recipient Entity
BCSD RESEARCH INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943959491
Principal investigator 1 GlaxoSmithKline, LLC. $259.00 03/01/2022 Non-covered Recipient Entity
BCSD RESEARCH INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943959495
Principal investigator 1 GlaxoSmithKline, LLC. $259.00 03/01/2022 Non-covered Recipient Entity
BCSD RESEARCH INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943959497
Principal investigator 1 GlaxoSmithKline, LLC. $259.00 03/01/2022 Non-covered Recipient Entity
BCSD RESEARCH INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943959499
Principal investigator 1 GlaxoSmithKline, LLC. $259.00 03/01/2022 Non-covered Recipient Entity
BCSD RESEARCH INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943959505
Principal investigator 1 GlaxoSmithKline, LLC. $259.00 03/01/2022 Non-covered Recipient Entity
BCSD RESEARCH INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943959507
Principal investigator 1 GlaxoSmithKline, LLC. $259.00 03/01/2022 Non-covered Recipient Entity
BCSD RESEARCH INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943959509
Principal investigator 1 GlaxoSmithKline, LLC. $259.00 03/01/2022 Non-covered Recipient Entity
BCSD RESEARCH INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943959511
Principal investigator 1 GlaxoSmithKline, LLC. $519.00 03/01/2022 Non-covered Recipient Entity
BCSD RESEARCH INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943959513
Principal investigator 1 GlaxoSmithKline, LLC. $464.00 03/01/2022 Non-covered Recipient Entity
BCSD RESEARCH INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943959515
Principal investigator 1 GlaxoSmithKline, LLC. $464.00 03/01/2022 Non-covered Recipient Entity
BCSD RESEARCH INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943959517
Principal investigator 1 GlaxoSmithKline, LLC. $1,718.00 03/01/2022 Non-covered Recipient Entity
BCSD RESEARCH INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943959519
Principal investigator 1 GlaxoSmithKline, LLC. $259.00 03/01/2022 Non-covered Recipient Entity
BCSD RESEARCH INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943959521
Principal investigator 1 GlaxoSmithKline, LLC. $259.00 03/01/2022 Non-covered Recipient Entity
BCSD RESEARCH INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943959523
Principal investigator 1 GlaxoSmithKline, LLC. $464.00 03/01/2022 Non-covered Recipient Entity
BCSD RESEARCH INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943959525
Principal investigator 1 GlaxoSmithKline, LLC. $464.00 03/01/2022 Non-covered Recipient Entity
BCSD RESEARCH INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943959529
Principal investigator 1 GlaxoSmithKline, LLC. $259.00 03/01/2022 Non-covered Recipient Entity
BCSD RESEARCH INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943959531
Principal investigator 1 GlaxoSmithKline, LLC. $259.00 03/01/2022 Non-covered Recipient Entity
BCSD RESEARCH INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943959533
Principal investigator 1 GlaxoSmithKline, LLC. $259.00 03/01/2022 Non-covered Recipient Entity
BCSD RESEARCH INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943959539
Principal investigator 1 GlaxoSmithKline, LLC. $665.28 02/24/2022 Non-covered Recipient Entity
LA SALUD RESEARCH CLINIC INC
A PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P No dispute reported 06/30/2026 943959333
Principal investigator 1 GlaxoSmithKline, LLC. $417.60 02/17/2022 Non-covered Recipient Entity
BCSD RESEARCH INC
A 24-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE-BLIND, EFFICACY AN No dispute reported 06/30/2026 943959413
Principal investigator 1 GlaxoSmithKline, LLC. $91.00 01/26/2022 Non-covered Recipient Entity
BCSD RESEARCH INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943959353
Principal investigator 1 GlaxoSmithKline, LLC. $1,817.90 01/26/2022 Non-covered Recipient Entity
BCSD RESEARCH INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943959453
Principal investigator 1 PFIZER INC. $6,156.00 01/13/2022 Non-covered Recipient Entity
BCSD RESEARCH INC
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 949712523